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Abstract
Background: Hepatitis B virus (HBV) carriers worldwide number approximately 240 million people and around
780,000 people die every year from HBV infection. HBV entry and uptake are functionally linked to the presence of
the human sodium-taurocholate cotransporting peptide (hNTCP) receptor. Recently, our group demonstrated that
human umbilical cord matrix stem cells (UCMSCs) become susceptible to HBV after in-vitro hepatogenic
differentiation (D-UCMSCs).
Methods: In the present study, we examined the involvement of hNTCP in governing D-UCMSC susceptibility to
HBV infection by characterizing the modulation of this transporter expression during hepatogenic differentiation
and by appreciating the inhibition of its activity on infection efficacy.
Results: We show here that in-vitro hepatogenic differentiation upregulated hNTCP mRNA and protein expression as
well as its activity in D-UCMSCs. Pre-treatment of D-UCMSCs with taurocholate, a specific NTCP substrate, blocked their
infection by HBV which supports the crucial involvement of this transporter in the early steps of the virus entry.
Conclusion: Altogether, our data support the usefulness of D-UCMSCs as a unique human and non-transformed in-vitro
model to study the early stages of HBV infection thanks to its ability to endogenously regulate the expression of hNTCP.
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Background
Human hepatitis B virus (HBV) is a human pathogen with
a restricted host range and a high specificity for liver cells.
HBV infection affects 240 million people worldwide, and
its transmission principally occurs during the neonatal
period and early infancy [1]. Prophylactic vaccination
against HBV has decreased the rate of chronic carriers by
70–90%. However, 10–30% of neonates do not respond to
the vaccine and have an elevated risk of developing
hepatocellular carcinoma later in adulthood [1]. Currently,
there are two common anti-HBV therapies available: 1)
nucleos(t)ide analogs that inhibit viral replication; and 2)
conventional interferon (IFN)-alpha therapies that stimu-
late the immune system and indirectly block viral protein
translation [2].
However, both therapies fail to eradicate infection as
they are only blocking the viral genome replication, and
neither eliminate the HBV covalently closed circular DNA
(cccDNA) that serves as a long-lived episomal transcrip-
tional template for HBV replication and reservoir for viral
persistence, nor do they prevent entry and thus (re)infec-
tion of naive hepatocytes [3]. An alternative strategy
would be the blockade of the viral entry process since, by
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acting on the cellular host components, it may avoid the
development of drug-resistant viruses and, most import-
antly, it stops the process of re-infection such as after liver
transplantation [4]. The lack of a fully suitable and easily
available HBV in-vitro infection model hampers in-depth
investigations of the HBV molecular entry mechanisms.
A few infection models have been developed and all of
them present common suboptimal features [5]. Only pri-
mary human hepatocytes (PHHs) and hepatocytes of
Tupaia belangeri (PTH) are susceptible to HBV infection
in vitro, but their rapid de-differentiation in culture and
low resistance to cryopreservation are strong limitations
for regular availability. Alternatively, HepaRG cells are the
only established cell line susceptible to HBV entry and
replication after dimethyl sulfoxide (DMSO)-induced dif-
ferentiation/infection [6, 7]. With the recent discovery of
the sodium-taurocholate cotransporting peptide (NTCP)
as the HBV/HDV receptor [8], new NTCP-based culture
systems have been developed to study HBV entry mecha-
nisms [9]. Among these, HepG2 clone lines overexpress-
ing NTCP have been successfully generated and can allow
70% of infection efficiency by using 2.5% DMSO [7]. How-
ever, both HepG2-NTCP and HepaRG cells present
chromosomal abnormalities besides the requirement of
DMSO for efficient infection [5, 7].
Thanks to their self-renewal and multilineage differen-
tiation potential, mesenchymal stem cells (MSCs) may
be considered a valid alternative source for studying
virus-cell interactions. The Wharton’s jelly of the umbil-
ical cord (UC) is a mucoid connective tissue [10] from
which MSC (UCMSCs) can be easily and reproducibly
isolated. These cells are able to significantly differentiate
at the morphological, genetic, and functional levels into
hepatocyte-like cells (D-UCMSCs) [11]. We have previ-
ously shown that D-UCMSCs allow HBV attachment
and entry under polyethylene (PEG) and DMSO-free
conditions, but not in their undifferentiated naive state
[12]. These findings suggest that the infection process in
D-UCMSCs is most probably mediated by an induced
cell surface determinant of hepatocytic lineage.
In the present study, we examined the susceptibility of D-
UCMSCs to HBV infection in relation to a functional
NTCP expression during hepatogenic differentiation. We
prove that D-UCMSCs displayed an upregulated NTCP ex-
pression at both mRNA and protein levels, as well as a sig-
nificant increase of its uptake activity. We also found that
increased NTCP expression occurred at the last maturation
step of a three-step differentiation protocol and was dexa-
methasone (Dexa)-dependent, as it could be inhibited by
the anti-glucocorticoid antagonist RU486. Finally, we prove
that HBV entry in D-UCMSCs is NTCP-mediated since
pre-treatment of D-UCMSCs with taurocholate, a specific
NTCP substrate and competitive inhibitor of HBV entry,
blocked HBV infection. These data consolidate our previous
finding regarding the susceptibility of D-UCMSCs for HBV
infection [12] and highlight the usefulness of such in-vitro
cell model to investigate early stages of viral transmission by
modulating NTCP expression.
Methods
Isolation and culture of UCMSCs
UCMSCs were isolated from the umbilical cord Wharton’s
Jelly by using an optimized isolation protocol as compared
to the one we previously documented [11]. These changes
have significantly enhanced the yield of recovered cells per
weight of material as well as their quality, which has im-
proved the standardization of cell plating density and the
emergence period. Briefly, umbilical cords were collected
in a specific conservation solution (HBSS without Ca2+
and Mg2+, 10% Fungizone, 1% penicillin/streptomycin (P/
S); Life Technologies) at 4 °C and processed within 24 h.
After extensive washing with phosphate-buffered saline
(PBS) supplemented with 1% P/S, veins and arteries were
removed; the remaining tissue was minced and incubated
with digestion solution (HBSS (Life Technologies), cal-
cium chloride 10 mM (Sigma), collagenase D (0.2% (w/v);
Roche) and hyaluronidase (100 U/ml; Roche)) for 90 min
at 37 °C with shaking at 250 rpm. After centrifugation, cell
counting and viability were evaluated prior to plating.
Cells were suspended in expansion medium (Dulbecco’s
modified Eagle medium (DMEM; 1 g/L glucose (Life
Technologies), 20% fetal bovine serum (Life Technolo-
gies), and 1% P/S (Life Technologies)) and seeded at
10,000 cells/cm2 on plastic tissue culture flasks (Greiner
Bio-One BVBA/SPRL, Belgium) at 37 °C in humidified at-
mosphere (5% CO2). Twenty-four hours later the medium
was changed to remove debris and non-adherent cells,
whereas further medium changes were performed twice a
week. After two sequential passages, well-characterized
UCMSCs were cryopreserved until use. In the current
study, UCMSCs were used between passage 4 and 10.
In vitro hepatogenic differentiation
Differentiation studies were conducted on UCMSCs that had
been seeded at 10,000 cells/cm2 on collagen I-coated flasks
(BD). After reaching 90% confluence, the expansion medium
was removed, cells were washed once with sterile PBS, and
hepatogenic differentiation was started by switching to
Iscove’s modified Dulbecco’s medium (IMDM; Life
Technologies) serum-free medium in which specific growth
factors/cytokines (Perpotech EC Ltd.) were added as a se-
quential multi-step protocol. Step 1 (20 ng/mL epidermal-
growth factor (EGF) and 10 ng/mL basic fibroblast growth
factor (bFGF)) lasted for 2 days. Then, Step 2 (20 ng/mL
bFGF, 10 ng/mL hepatocyte growth factor (HGF), insulin-
selenium-transferrin (ITS; Life Technologies) and 0.61 g/L
nicotinamide (Sigma)) lasted for 9 days including three
medium changes. Subsequently, Step 3 (20 ng/mL oncostatin
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M (OSM), 20 ng/mL HGF, 1% ITS, 0.61 g/L nicotinamide
and 10–6 M Dexa (Sigma)) lasted for another 9 days includ-
ing three medium changes. Recovered differentiated cells
were analyzed at the expression and functional levels to
evaluate the quality of the acquired hepatogenic differenti-
ation. Once the hepatogenic differentiation protocol was
completed, D-UCMSCs were incubated in a maintenance
medium (IMDM supplemented with 10–6 M Dexa and
20 ng/mL HGF) in order to sustain the acquired hepatic
features. Maintenance medium was also used during the
HBV infection studies.
HBV source and in-vitro infection of D-UCMSCs
HBV batch production was conducted in collaboration
with the Rega Institute. The viral source was produced
in vitro using the HepAD38 cell line containing HBV
(genotype D, subtype ayw). Viral stocks were quantified
and concentrated at 107–108 HBV/mL from HepAD38
conditioned medium, as previously reported by our
group [12]. D-UCMSC infection was accomplished by
incubating the virus for 24 h at 37 °C. Viral replication
was monitored for 4 days post-infection every 24 h. In-
fection efficiency was established using different viral
loads (105, 104, and 103 multiplicities of infections
(MOIs)). MOIs of 2500 were used as a standard infec-
tion inoculum in the study.
Quantitative reverse-transcription polymerase chain
reaction (qPCR) analysis
RNA from both UCMSCs and D-UCMSCs was extracted
with Tripure reagent (Roche) following the manufacturer’s
instructions, and was quantified using a Nanodrop™
(Thermo Scientific, USA). Two micrograms of total RNA
were reverse transcribed (RT) through a High Capacity
cDNA Reverse Transcription Kit (Life Technologies). Vari-
ous gene mRNAs were analyzed by TaqMan® gene expres-
sion assays using StepOnePlus (Thermo Fisher, USA)
(Table 1). The delta delta comparative method was per-
formed between UCMCSCs and D-UCMSCs by initially
selecting from 32 candidate housekeeping genes, the
TATA-Box binding protein (TBP) and the Processing of
precursor 4 (POP4) based on qBASE PLUS software ana-
lysis (Biogazelle, Belgium).
Intracellular and extracellular HBV quantification analyses
Intracellular DNA and RNA were extracted from infected
D-UCMSCs to analyze the HBV cccDNA and pregenomic
(pg)RNA transcripts, respectively, as key markers of HBV
infection. For HBV cccDNA analysis, DNA was extracted
by Tris-Phenol and treated by RNase A to exclude the pres-
ence of contaminating RNA [13]. Samples were then quan-
tified by Nanodrop and analyzed by the digital droplet
qPCR method (ddqPCR). With this method, HBV cccDNA
TaqMan assay [14] detection was conducted in parallel with
RNase P assay (multiplex assay) to normalize the cccDNA
copies per cell (RNase P). cccDNATaqMan assay amplifica-
tion products were analyzed on 2% agarose gel. Viral RNA
extraction was conducted as described in the RT-qPCR sec-
tion. HBV transcripts were detected using the RC01 assay
(Thermo Fisher; ID: AIS07DM), as previously validated
[12]. The RC01 assay amplifies a specific region common
to both HBV pgRNA and preC major viral transcripts.
Relative quantification analysis of HBV transcripts was nor-
malized by using two reference genes as described above.
Extracellular DNA extraction from infected D-USMSC
conditioned medium was performed using the PureLink®
Viral RNA/DNA Mini Kit (Life Technologies) according to
the manufacturer’s protocol. Briefly, DNA was eluted in
25 μL of water, of which 5 μL was analyzed by qPCR to de-
termine the amount of HBV relaxed circular (RC) DNA
viral particles secreted by D-UCMSCs. Absolute quantifica-
tion by the WHO International standards linear regression
method allowed us to evaluate the copy number of secreted
viral particles by D-UCMSCs. Primer and probe sequences
are reported in Table 2.
CYP3A4 activity assay
The hepatogenic differentiation potential of UCMSCs was
assessed by the Lytic CYP3A4 P450-Glo™ assay (Promega,
Belgium) following the manufacturer’s instructions with
slight modifications. To measure CYP3A4 activity, each re-
action contained 0.1 pmol of luciferin-IPA substrate which
was incubated with 200,000 cells/well in a 96-well white
plate for 4 h at 37 °C. The luminescent signal was produced
by adding luciferin detection reagent for an additional
Table 1 Primers used for differentiated umbilical cord
mesenchymal stem cell gene expression analysis
Gene Code Supplier
NTCP Hs00161820_m1 ThermoFisher
CYP3A4 Hs00604506_m1 ThermoFisher
CYP7A1 Hs00167982_m1 ThermoFisher
POP4 Hs99999910_m1 ThermoFisher
TBP Hs00198357_m1 ThermoFisher
Table 2 Primers used for hepatitis B virus quantification analysis
and cell copy number
Sequence Code/catalog number Supplier
HBV RC DNA_F CAGCACCATGCAACTTTTTCAC Thermo Fisher
HBV RC DNA_R ATCAATGTCCATGCCCCAAA Thermo Fisher
HBV RC DNA_probe TGTCCTACTGTTCAAGCC Thermo Fisher
HBV cccDNA_F CTCCCCGTCTGTGCCTTCT Tibmolbiol
HBV cccDNA_R GCCCCAAAGCCACCCAAG Tibmolbiol
HBV cccDNA_probe CGTCGCATGGARACCACCGT
GAACGCC
Tibmolbiol
RNase P 4316831 Thermo Fisher
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20 min at room temperature and under gentle shaking.
Plate reading was fixed at a 10-s acquisition time by a
luminometer (VICTOR 3, PerkinElmer, USA). CYP3A4
activity is expressed as the relative light units (RLU) net sig-
nal, which is calculated by subtracting no-cell control
values (substrate only) from test compound values (cell and
substrate).
Western blot analysis
Total protein lysates were obtained by dissolving cell pellets
in RIPA buffer (50 mM Tris Base, pH 8.0, 150 mM NaCl,
1% Triton X-100 (Sigma), 0.5% deoxycholate (Sigma,
Belgium), 0.1% SDS, supplemented with protein inhibitors
cocktail without EDTA (Roche)). Protein samples were
shortly sonicated and incubated for 30 min at 4 °C prior to
sample clarification by centrifugation (15 min 17,000 rpm at
4 °C). Subsequently, sample supernatants were collected
and total protein quantification was performed (BCA Quan-
tification kit, Thermo Fisher). Ninety micrograms of total
protein extracts were dissolved in loading buffer (100 mM
Tris-HCl (pH 6.8), glycerol 2% (v/v), SDS 4% (w/v), DTT
200 mM, bromophenol blue 0.2%), denatured at 95 °C for
5 min, loaded onto a 10% Tris-glycine SDS-PAGE gel for
protein separation, and transferred overnight at 4 °C onto
PVDF membranes. Thereafter, membranes were incubated
with 5% bovine serum albumin (BSA) blocking solution for
1 h at room temperature. Primary antibodies (Table 3) were
incubated overnight at 4 °C; membranes were washed three
times with PBS-Tween-20 (T) (1%; Sigma) and then incu-
bated with fluorescently labeled secondary antibodies (Bio-
tium) for 40 min at room temperature. Membranes were
then washed (3× PBS-T) and fluorescence signals were de-
tected by Li-cor scanner (Odyssey). Quantification analysis
was performed by Image Studio Lite Software (Odyssey).
For NTCP deglycosylation assay, 90 μg of total protein ex-
tracts were treated with PGNase F (New England Biolabs)
for 2 h at 37 °C in RIPA buffer. A goat polyclonal anti-actin
antibody (1:2000; sc-1616, Santa Cruz Biotechnology)
served as the loading control
Indocyanine green (ICG) uptake/release assay
ICG is a non-toxic tricarbocyanin dye exclusively taken up
by hepatocytes through the LST1 (Liver-Specific organic
Transporter-1). Naive and D-UCMSCs were incubated for
5 h with 1 mg/mL ICG (Sigma) at 37 °C. The uptake and
the clearance of ICG were assessed on the same micro-
scopic fields using a white light inverted microscope
(Leica DM IL).
Taurocholate uptake assay
After culture medium removal, cells were washed twice
and incubated for 10 min with transport assay buffer at
37 °C (5.3 mM KCl, 1.1 mM KH2PO4, 0.8 mM MgSO4,
1.8 mM CaCl2, 11 mM D-glucose, 10 mM HEPES, and
136 mM NaCl (sodium-containing buffer)) [15]. To evalu-
ate NTCP uptake activity, cells were incubated with pre-
heated sodium-containing buffer supplemented with the
radiolabeled [3H]-taurocholic acid substrate (1 μCi/ml;
Perkin Elmer, Belgium). Different concentrations were ap-
plied (0 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, and 1 μM)
either in the presence or in the absence of sodium ions on
both naive UCMSCs and D-UCMSCs. Uptake was
stopped by adding ice-cold PBS containing 0.2% w/v BSA
[16]. After a final washing step with ice-cold PBS, cells
were lysed with mammalian protein extraction reagent
(Pierce, Belgium) and the intracellular accumulation of
the radiolabeled substrate was measured using liquid
scintillation counting (Tri-Carb, Perkin Elmer, Belgium).
Statistical analyses
Statistical analysis was performed with GraphPad PRISM
6 Software (GraphPad Software, USA). Mann-Whitney
U, Wilcoxon signed-rank, one-sample two-tailed t test,
and one-way analysis of variance (ANOVA) tests were
used, as appropriate, and p < 0.05 was considered signifi-
cant. Values are expressed as mean ± standard deviation
(SD) or mean ± standard error of the mean (SEM).
Results
The effect of hepatogenic differentiation on UCMSCs
All freshly isolated UCMSCs were characterized by flow
cytometry using the MSC markers CD90, CD105, CD73,
and CD45 (Additional file 1: Figure S1A) and subsequently
cryopreserved as described in the Methods section.
Hepatogenic differentiation was conducted on thawed
UCMSCs with an optimized three-step protocol. Figure 1a
shows that hepatogenic differentiation of UCMSCs signifi-
cantly upregulates CYP3A4 mRNA expression in D-
UCMSCs by at least 600 fold (n = 3) as compared to their
naive counterparts (t test p = 0.005). Western blot analysis
confirmed the increased CYP3A4 protein expression in
D-UCMSCs. Indeed, a corresponding 55-kDa band was
significantly induced in D-UCMSCs as compared to naive
UCMSCs (Fig. 1b). Finally, to assess protein functionality,
CYP3A4 activity was also assayed in D-UCMSCs. Figure 1c
shows a significant increase in CYP3A4 activity in D-
UCMSCs by at least 10 fold (n = 16) compared to naive
Table 3 Primary antibody references and working concentrations
Antigen Supplier Reference Species Type Dilution
NTCP Pr. Bruno
Stieger
de Graaf et al.,
2011 [17]
Rabbit Polyclonal 1/1000
NTCP Sigma HPA042727 Rabbit Polyclonal 1/1000
CYP3A4 Enzo Life
Sciences
BML-CR3340-0025 Rabbit Monoclonal 1/1000
GAPDH Abcam ab8245 Mouse Monoclonal 1/10.000
Actin Sigma A2066 Rabbit Polyclonal 1/1000
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UCMSCs (n = 8) (t test; p < 0.0001). These results indicate,
along with other in-house specifications (Additional file 1:
Figure S1A), that D-UCMSCs from the optimized isola-
tion protocol acquired similar hepatocyte-like features as
previously reported (Additional file 1: Figure S1B) [12].
HBV infection of D-UCMSCs
Infection experiments were conducted over 4 days after
incubating D-UCMSCs with HBV for 24 h at 37 °C. To
assess the relative infectivity of HBV inocula, D-
UCMSCs were infected with three viral titers (100, 1000,
and 10,000 virions/cell determined as viral genome
equivalents). As a result, we established 2500 HBV viral
particles per cell as a standard infection protocol of D-
UCMSCs for the current study (Additional file 1: Figure
S2A). Soon after D-UCMSC infection, the presence of
viral genome (cccDNA) became measurable by ddPCR.
After validation of this sensitive method for DNA quan-
tification (Additional file 1: Figure S2B), we accurately
determined the absolute copy numbers of cccDNA per
cell. Hence, Fig. 2a shows that cccDNA formation was
detected over 4 days post-infection indicating its rapid
formation in the nucleus of D-UCMSCs. Intracellular
viral RNA transcript formation was monitored by RT-
qPCR analysis of HBV pgRNA/preC transcripts. Fig-
ure 2b shows that viral replication in D-UCMSCs was
successfully established and was sustained over 4 days
post-infection. Finally, to confirm that infected D-
UCMSCs support the entire HBV life cycle, production
and secretion of RC DNA containing HBV virions was
measured by absolute qPCR quantification. As described
in Fig. 2c, D-UCMSCs produced detectable amounts of
HBV virions and increased progeny production overtime
as compared to day 1 post-infection.
NTCP mRNA modulation in D-UCMSCs
At the end of the hepatogenic differentiation process, D-
UCMSCs were analyzed to test if NTCP expression was
modulated. NTCP mRNA expression levels were initially
measured by RT-qPCR. In Fig. 3a, we show that D-
UCMSC expression of NTCP mRNA (60.0 ± 44.5 SD, n =
5) was significantly increased as compared to naive
UCMSCs (1.6 ± 1.2 SD, n = 3; p = 0.0357 by Mann-
Whitney U test). To evaluate the kinetics of NTCP mRNA
upregulation, the end point of each of the three steps of
the hepatogenic differentiation protocol was analyzed. Fig-
ure 3b shows that NTCP mRNA was significantly upregu-
lated only at the end of the last step of the hepatogenic
differentiation as compared to Step 1 (p = 0.0047; t test)
and Step 2 (p = 0.0047; t test). Moreover, NTCP expres-
sion continued increasing (p < 0.001; t test) for at least
4 days after the end of the hepatogenic differentiation
while only the maintenance medium containing Dexa and
HGF was used (Fig. 3c). One of the main components of
the maturation step that could modulate NTCP expres-
sion is Dexa. Consequently, NTCP mRNA levels were
measured in D-UCMSCs on Dexa treatment with three
different concentrations (10 nM, 100 nM, and 1000 nM).
As shown in Fig. 3d, Dexa enhances NTCP mRNA ex-
pression in a dose-dependent (p = 0.009) and also in a
time-dependent manner in D-UCMSCs (Additional file 1:
Figure S3C). Finally, to prove that NTCP expression was
directly induced by 1 μM Dexa via the glucocorticoid re-
ceptor (GR), we tested a known GR antagonist on D-
UCMSCs, the anti-glucocorticoid RU486 which blocks the
ligand-induced action of GR. Indeed, the addition of 1 μM
RU486 with Dexa after 4 days of treatment significantly
reduced NTCP mRNA expression in D-UCMSCs and
fully inhibited the effect of Dexa as compared 1 μM Dexa
without RU4846 (p < 0.001; t test) (Fig. 3e).
a b c
Fig. 1 Hepatogenic differentiation of UCMSCs. a CYP3A4 mRNA expression is significantly induced in differentiated umbilical cord mesenchymal stem
cells (D-UCMSCs). Values are expressed as fold increase (669 ± 71 SD; n = 3 vs. control UCMSCs (n = 3). Gene expression was normalized by POP4 and
TBP housekeeping genes (p = 0.005; Mann-Whitney U test). b Upregulation of CYP3A4 protein expression in D-UCMSCs is demonstrated by Western
blot; 90 μg of total protein extracts were loaded per well. Actin was used as the loading control. The blot is representative of three different donors
tested. c CYP3A4 activity was also enhanced as demonstrated by using Luciferase assay in D-UCMSCs (1069 ± 157 SD, n = 16) when compared to
UCMSCs (CTRL; 153 ± 32 SD, n = 8; p < 0.0001 by Mann-Whitney U test). Values are expressed as the relative light unit (RLU) net signal
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NTCP protein expression in D-UCMSCs
To confirm that NTCP mRNA expression can be effect-
ively correlated to an enhanced protein expression, we
used Western blot assay. In D-UCMSCs, high expression
of a glycosylated NTCP could be demonstrated (visual-
ized by Western blot as a prominent 55 kDa band;
Fig. 4a) as compared to naive UCMSCs. Furthermore, to
functionally characterize NTCP transporter activity in
D-UCMSCs, ICG clearance assay was applied before and
after hepatogenic differentiation. ICG is a compound
that mimics organic anions, such as bile acid and biliru-
bin, and has been shown to be transported by NTCP
[17]. As depicted in Fig. 4b, we could observe that ICG
uptake was specific for D-UCMSCs (5 h post-treatment)
that were also able to release it after 5 days. These
results suggested that D-UCMSCs can take up ICG via
NTCP-mediated active transport, even though we can-
not exclude the involvement of additional transporters
such as OATPs isoform 3A1 [17]. Finally, to confirm
NTCP-specific sodium-dependent transport activity, we
performed taurocholate (TC) uptake assays with or with-
out sodium for both UCMSCs and D-UCMSCs (Fig. 4c).
In line with an overall low NTCP expression in
UCMSCs, the TC uptake capacity of UCMSCs was not
significantly changed in sodium versus sodium-free
conditions (Vmax = 1.460; km = 6.180 μM). By contrast,
in D-UCMSCs overall TC uptake rates were markedly
increased under conditions in which sodium ions were
available (Vmax = 10.791; km = 15.65; R2 = 0.96) as com-
pared to sodium-free conditions (Vmax = 821; km = 0.817;
R2 = 0.807), particularly at 1 μM.
Inhibition of HBV entry in D-UCMSCs by taurocholate
To prove that D-UCMSC infection by HBV was mediated
by NTCP, we treated D-UCMSCs with TC, a specific NTCP
inhibitor [7], before and during the complete time span of
the infection experiments. To inhibit the HBV entry
process we used the same TC concentrations as previously
documented in other studies to inhibit HBV entry [7]. To
assess the degree of infection viral particles, supernatants
were collected at day 4 from D-UCMSC conditioned
medium and qPCR absolute quantification of HBV RC
DNA virions was performed. In Fig. 5a we show that in all
TC concentrations tested the total viral production over
4 days post-infection was significantly reduced while
500 μM TC most profoundly influenced the infection
process in D-UCMSCs. To evaluate the effect of viral inhib-
ition in D-UCMSCs, we compared viral production be-
tween D-UCMSCs treated with TC and non-treated
controls at day 4 post-infection. In Fig. 5b, we show that
125 μM TC treatment reduced viral production in D-
UCMSCs by 50% (0.5 ± 0.2 SD) as compared to untreated
cells. In addition, infected D-UCMSCs treated with another
physiological NTCP substrate taurochenodeoxycholate
(TCDC) proved that TCDC treatment at all concentrations
tested (0.2 μM, 0.75 μM, 1 μM, 1.25 μM) also inhibited viral
production at day 4 post-infection as compared to non-
treated D-UCMSCs (n = 2) (Additional file 1: Figure S5B).
Hepatocytic gene modulation in HBV-infected D-UCMSCs
Finally, to study HBV-cell interactions, we compared D-
UCMSCs that had been infected with HBV to non-infected
cells. As depicted in Fig. 6, HBV infection significantly
Fig. 2 HBV infection kinetics in D-UCMSCs. a Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) kinetic: infected D-UCMSC samples
were collected during 4 days post-infection and were analyzed by ddPCR multiplex assay. HBV cccDNA biogenesis was detectable in D-UCMSCs
starting at day 1 up to day 4 post-infection (n = 3). The cell copy number was calculated by RNase P genome detection. Absolute values are
expressed as HBV cccDNA copies per cell (donors 112, 114, and 116). b HBV pgRNA detection: viral transcripts (pregenomic (pg) and preC RNAs)
were detected by qPCR during HBV infection kinetic in D-UCMSCs. Viral RNAs were detected starting at day 1 and expressed as fold-increase in
time as compared to cells infected after 24 h after primary infection (donors 112 and 116). Relative quantification analysis of HBV pg/pc RNAs was
normalized by using TBP and POP4 reference genes. c HBV relaxed circular (RC) DNA virion secretion: D-UCMSC infection kinetic studies show an
increased production of HBV infectious particles over 4 days (p < 0.05). Absolute quantification of HBV RC DNA positive virions is expressed as fold
change versus cells 24 hours after primary infection (donors 112 and 116)
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decreased the CYP3A4 mRNA expression (37 ± 0.5 SEM) as
compared to non-infected (462 ± 47.5 SEM) levels, whereas
CYP7A1 mRNA expression increased (5.29 ± 0.5 SEM) as
compared to non-infected (2.28 ± 0.5 SEM) levels. With re-
spect to NTCP, a tendency of an increased expression was
observed as compared to non-infected cells.
Discussion
NTCP is the major uptake transporter for bile salts in he-
patocytes [18]. Recently, NTCP has been discovered to be
the first functional HBV receptor to enable HBV entry in
NTCP-expressing permissive cells. The present study
characterizes the expression of NTCP in D-UCMSCs as a
marker of viral entry and as a new indicator of stem cell
hepatogenic differentiation quality [18]. None of the previ-
ous studies conducted on other MSCs has ever evaluated
NTCP expression upon an in-vitro hepatogenic differenti-
ation protocol. Indeed, in D-UCMSCs, NTCP mRNA and
protein expression was upregulated and correlated with
an enhancement of TC uptake activity as compared to
naive UCMSCs (Figs. 3 and 4). We also demonstrate that
NTCP inhibitors decreased HBV entry in D-UCMSCs as
compared to non-treated cells, suggesting a competitive
binding for NTCP (Fig. 5). Our data prove that D-
UCMSCs express functional NTCP and that in this in-
vitro infection model of HBV entry depends on its func-
tionality. Isolated hepatocytes, in comparison to D-
UCMSCs, constitutively express NTCP, but rapidly lose
Fig. 3 Characterization of NTCP mRNA expression in D-UCMSCs. a Sodium-taurocholate cotransporting peptide (NTCP) mRNA expression: hepatogenic
differentiation induces NTCP mRNA modulation in differentiated umbilical cord mesenchymal stem cells (D-UCMSCs; 60.0 ± 44.5 SD, n = 5) as compared
to UCMSCs (1.6 ± 1.2 SD, n = 3; p = 0.0357 by Mann-Whitney U test, two-tailed). The relative quantification method was normalized using TBP and
POP4 reference genes. b NTCP expression at Step 3 of differentiation: the third step of hepatogenic differentiation induces NTCP mRNA expression
(5.9 ± 0.2 SD) as compared to Step 2 (0.6 ± 0.2 SD) and Step 1 (0.2 ± 0.7 SD). Values are expressed as fold increase compared to UCMSCs (p = 0.0047 by
unpaired t test, two-tailed; n = 3). c NTCP mRNA expression post-hepatogenic differentiation: maintenance medium containing dexamethasone (Dexa)
10–6 M and HGF 10 ng/ml was added at the end of the hepatogenic differentiation protocol. The NTCP mRNA expression kinetic was sustained and
increased at day 4 post-differentiation (p = 0.05 by Mann-Whitney U test, one-tailed; n = 3). Values are expressed as ΔΔ Ct fold increase as compared to
day 0 (end of differentiation). d The effect of Dexa on NTCP mRNA expression: D-UCMSCs were treated with Dexa (10 nM, 100 nM, and 1000 nM) at
Step 3 of hepatogenic differentiation. NTCP mRNA levels were measured by RT-qPCR (n = 2). NTCP expression was increased in a dose-dependent
manner by Dexa (6.5 ± 1.6 SD 10 nM; 8.4 ± 0.6 SD 100 nM; and 16.1 ± 1.2 SD 1000 nM). Values are expressed as ΔΔ Ct fold increase versus Step 2
(end of differentiation). e Inhibition of NTCP mRNA expression in D-UCMSCs treated by RU486. 1 μM RU486 was added at the end of hepatogenic
differentiation for 4 days with Dexa 10–6 M. qPCR analysis revealed that NTCP mRNA expression was significantly reduced by treatment with 1 μM
RU486 as well as CYP3A4 mRNA expression (p < 0.001 by multiple t test). Values expressed as relative quantity compared to UCMSCs
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Fig. 4 NTCP protein modulation in D-UCMSCs. a Western blot analysis of sodium taurocholate cotransporting peptide (NTCP) protein expression in
differentiated umbilical cord stem cells (D-UCMSCs): an NTCP 55 kDa band was detected in D-UCMSCs (n = 3). Ninety micrograms of total protein
samples were loaded per lane. NTCP was detected by anti-NTCP primary antibody (kind gift from Prof. Bruno Stieger). Actin was used as the loading
control. b ICG functional uptake and release assay. D-UCMSCs acquire both the ability to internalize (left panel) and to release ICG (right panel). Pictures
were taken at 5 h and at 5 days post-treatment, respectively (magnification 200×) (n = 3). In contrast, naive UCMSCs are not able to either internalise
nor release ICG as compared to D-UCMSCs (n = 3). c Taurocholate (TC) uptake assay with and without sodium. Uptake was measured in UCMSCs
(n = 2) and D-UCMSCs (n = 3) using increasing concentrations of TC. UCMSCs do not uptake TC efficiently with and without sodium (left panel).
D-UCMSCs increase TC uptake function with or without sodium ((Vmax = 1,460 km= 6.180). TC uptake under sodium conditions significantly increased
at 1 μM (Vmax = 10,791) as compared to the sodium-free condition (Vmax = 821). Values are expressed as TC uptake (pmol/min/mg protein)
Fig. 5 Inhibition of HBV entry in D-UCMSCs. a Inhibition of viral entry by taurocholate (TC) treatment: infected D-UCMSCs were treated 2 h prior to
and during infection with different concentrations of TC. Supernatant was collected at day 4. Secreted HBV relaxed circular (RC) DNA virions were
quantified by absolute qPCR assay. Values are expressed as absolute copys numbers of HBV RC DNA infectious virions at different TC concentrations
and produced by three different donors. b Infected D-UCMSC TC treatment relative to non-treated: treated cells as compared to non-treated cells
present a substantial decrease in HBV production when increasing TC concentrations are used (n = 3). Absolute quantification of HBV RC DNA positive
virions is expressed as fold increase versus cells 24 h after primary infection
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NTCP activity unless complex culture conditions are opti-
mized [15]. As such, a valid alternative to PHH culture is
the use of D-UCMSCs to specifically modulate NTCP ex-
pression by using dexamethasone and avoiding complex
culture conditions that might interfere with viral entry.
HBV entry is a key process for developing a productive
infection. Hence, it represents an attractive molecular target
for the design of new antiviral strategies to block viral re-
infection, a still poorly understood process [9]. The ex-
tremely restricted tropism of HBV and the limited in-vitro
models available have hampered its study. Glycosaminogly-
cans (GAGs), in particular heparan sulfate proteoglycans
(HSPGs), have been demonstrated to be essential for the
initial HBV attachment process, but these are not sufficient
for infection simply because these proteoglycans are not
specific for susceptible cells [19, 20]. Indeed, the findings of
Schulze et al. were recently confirmed by the identification
of a subclass of HSPGs called glypican 5 (GPC-5) [21]. In
contrast, HBV binding and uptake depend on the expres-
sion and function of the NTCP transporter, strongly sug-
gesting that this membrane-bound protein is the cell host
determinant for HBV tropism [7, 8].
Nevertheless, other molecular determinants might be
required for a productive and efficient infection since it
has been reported that 100% infection efficiency is not
reached even in transfected NTCP-overexpressing cells
[8, 22, 23]. Therefore, the optimization of new in-vitro
infection models is needed to investigate the detailed
mechanisms of the HBV viral entry process and its
modulation in greater depth. At present, HBV in-vitro in-
fection models are limited and are all suboptimal. Several
common disadvantages of currently available cell systems
are a low replication efficiency, high MOIs needed, and
the use of molecular adjuvants, such as DMSO and/or
PEG, to enhance infection [5]. Therefore, D-UCMSCs are
a suitable tool for the study of HBV early events, although
it should be noted that high MOIs are needed to produce
an efficient infection. Nevertheless, molecular adjuvants
are avoided in D-UCMSC infection studies which position
this cell model close to a more physiological condition
[12]. Our data also show that increased NTCP expression
occurs during the last step of the hepatogenic differenti-
ation via Dexa. This effect is mediated via GR activation
and suggests an indirect modulation of HBV infection
through this glucocorticoid receptor [24]. Indeed, RXR, a
transcription factor which binds to the NTCP promoter,
was recently proven to enhance HBV infection by upregu-
lating NTCP expression [25].
UCMSCs are easily and reproducibly isolated from a
regularly available source and maintain their features even
after cryopreservation. Upon in vitro hepatogenic differen-
tiation, D-UCMSCs express NTCP and enhance suscepti-
bility to HBV. Here, we describe D-UCMSC viral kinetics
and observe that the HBV infection process is rapid and
robust, with no cytopathic effect over 4 days post-
infection. To monitor the HBV life cycle, we analyzed D-
UCMSC supernatant for HBV RC DNA virions by qPCR
analysis. Indeed, the detection of mature virions repre-
sents indirect proof that pgRNA packaging and nucleo-
capsid formation are completed without error by D-
UCMSCs. Such results were validated after cccDNA de-
tection using ddPCR assay and by demonstrating the ex-
pression of pgRNA viral transcripts.
We monitored cccDNA biogenesis every 24 h in D-
UCMSCs over 4 days and found that the number of cccDNA
copies detected per cell was between 0.02 and 0.06, which is
higher than that previously reported at 24 h post-infection
(<0.02 copies/cell) [12]. However, it is still less than the
cccDNA detected in HepaRG (0.5 copies/cell), PHH (1 to 2
copies/cell), and HepG2-NTCP (1 to 5 copies/cell) infection
models [26]. The low cccDNA copy number detected in D-
UCMSCs might be influenced by the non-use of adjuvants
during the infection step. Nevertheless, D-UCMSCs are a
valid model to study cccDNA formation and also a tool for
targeting the HBV genome, in which cccDNA biogenesis can
be monitored by quantitative ddPCR analysis.
To determine the critical involvement of functional
NTCP in HBV-induced infection of D-UCMSCs, we pre-
exposed the differentiated cells to TC and, as expected, a
marked decrease in HBV infection could be achieved,
clearly suggesting a competition between HBV binding and
TC for the available TC binding sites [7, 27]. Our findings
Fig. 6 HBV gene modulation in infected D-UCMSCs. Gene expression
analysis between HBV infected and non-infected cells shows that
sodium taurocholate cotransporting peptide (NTCP) expression was
not significantly modulated by HBV (p = not significant by multiple t
test; n = 3). In contrast, HBV infection significantly decreases CYP3A4
expression (462.6 ± 47.4 SEM; p = 0.0008) and increases CYP7A1
expression (2.2 ± 0.081 SEM; p = 0.005). Values are expressed as relative
quantity compared to UCMSCs that were not infected
Sargiacomo et al. Stem Cell Research & Therapy  (2017) 8:204 Page 9 of 11
are in line with previous reports demonstrating that the
NTCP substrates TC, TDC, and TCDC reduce infection by
interfering with the HBV viral entry process [7]. HBV can
modulate several cellular host pathways. Previous reports
have shown that cytochrome P450 isoforms (CYPs; liver-
specific enzymes) are modulated by HBV [28]. In particular,
CYP7A1 expression was found to increase in vivo post-
HBV infection [29]. In line with these findings, we could
demonstrate for the first time that HBV infection increases
CYP7A1 mRNA expression in D-UCMSCs, while CYP3A4
expression was decreased. No significant modulation of
NTCP expression was noticed post-HBV infection in D-
UCMSCs (Fig. 6). These experiments are the first attempt
to study hepatocytic gene modulation in infected D-
UCMSCs and demonstrate that virus-host interaction stud-
ies might be useful to investigate HBV liver-induced
diseases in a controlled microenvironment.
Conclusions
The present study proposes D-UCMSCs as a suitable
HBV infection system to study viral entry and the life
cycle. D-UCMSC HBV infection efficiency can be im-
proved by increasing the quality of differentiation and by
modulating NTCP expression, for instance as shown here
after the activation of GR by Dexa. A recent study on
iPSC-derived hepatocytes has used NTCP as a marker to
obtain a homogenous hepatocyte-like population express-
ing NTCP, but these authors did not prove infection with
HBV [30]. A similar enrichment approach might be suit-
able to differentiated D-UCMSCs in order to augment the
infection rate. Taken together, our results suggest that the
HBV life cycle depends on the expression and functional-
ity of NTCP in D-UCMSCs, which enables HBV entry
and modifies cellular gene expression patterns.
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